|
|
Article: Palatin Technologies Reports PT-141 Phase 1 Clinical Results.
- Article from:
- Business Wire
- Article date:
- May 31, 2001
CopyrightCOPYRIGHT 2001 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors & Health/Medical Writers
PRINCETON, N.J.--(BUSINESS WIRE)--May 31, 2001
Palatin Technologies, Inc. (AMEX: PTN) today announced positive results from its Phase 1 clinical safety study of PT-141, the company's lead investigational drug under study for the treatment of male erectile dysfunction (ED).
The trial was designed as a double blind, placebo-controlled, dose escalation study to evaluate the safety and pharmacokinetics (absorption of drug and blood plasma level of drug) at various doses and determine the maximum tolerated dose (MTD) in 56 normal volunteers. PT-141 was delivered as a nasal spray.
Participants in the ...